The concomitant use of lapatinib and paracetamol - the risk of interaction

Lapatinib is a tyrosine kinase inhibitor used for the treatment of breast cancer. Paracetamol is an analgesic commonly applied to patients with mild or moderate pain and fever. Cancer patients are polymedicated, which involves high risk of drug interactions during therapy. The aim of the study was t...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Invest New Drugs
Huvudupphovsmän: Karbownik, Agnieszka, Szałek, Edyta, Sobańska, Katarzyna, Grabowski, Tomasz, Klupczynska, Agnieszka, Plewa, Szymon, Wolc, Anna, Magiera, Magdalena, Porażka, Joanna, Kokot, Zenon J., Grześkowiak, Edmund
Materialtyp: Artigo
Språk:Inglês
Publicerad: Springer US 2018
Ämnen:
Preclinical Studies
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6153549/
https://ncbi.nlm.nih.gov/pubmed/29464465
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-018-0573-1
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk